专利检索 ap:("Baxter International Inc." OR "Baxter Healthcare S.A.") AND inv:"CANAVAGGIO, Michel" 第 1 页

1.

发明公开
FACTOR VIIA- (POLY) SIALIC ACID CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE 有权
标题翻译：凝血因子VIIa（POLY）SIALSÄUREKONJUGAT延长体内半衰期

公开(公告)号：EP2101821A1

公开(公告)日：2009-09-23

申请号：EP07865679.0

申请日：2007-12-14

申请人： Baxter International Inc. , Baxter Healthcare S.A.

发明人： TURECEK, Peter , SIEKMANN, Juergen , SCHEIFLINGER, Friedrich , CANAVAGGIO, Michel

IPC分类号： A61K47/48

CPC分类号： A61K47/4823 , A61K38/4846 , A61K47/549 , A61K47/61 , C12N9/6437 , C12N9/96 , C12Y304/21021 , Y02A50/463

摘要： The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (F VIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.

2.

发明授权
FACTOR VIIA- (POLY) SIALIC ACID CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE 有权
标题翻译：凝血因子VIIa（POLY）SIALSÄUREKONJUGAT延长体内半衰期

公开(公告)号：EP2101821B1

公开(公告)日：2014-08-13

申请号：EP07865679.0

申请日：2007-12-14

申请人： Baxter International Inc. , Baxter Healthcare SA

发明人： TURECEK, Peter , SIEKMANN, Juergen , SCHEIFLINGER, Friedrich , CANAVAGGIO, Michel

IPC分类号： A61K47/48 , A61P7/04

CPC分类号： A61K47/4823 , A61K38/4846 , A61K47/549 , A61K47/61 , C12N9/6437 , C12N9/96 , C12Y304/21021 , Y02A50/463

摘要： The present invention relates to a proteinaceous construct comprising plasmatic or recombinant factor VIIa (F VIIa) or biologically active derivatives thereof, which are bound to a carbohydrate moiety comprising 1-4 sialic acid units, wherein the in vivo half-life of the proteinaceous construct is substantially prolonged in the blood of a mammal, as compared to the in vivo half-life of a FVIIa molecule not bound to a carbohydrate moiety. The invention also provides a method for controlling bleeding in a mammal having a bleeding disorder due to functional defects or deficiencies of FVIIa, FVIII, or FIX. The invention also provides a method for controlling bleeding in a mammal during surgery or trauma.